TY  - CHAP
M1  - Book, Section
TI  - Clostridioides difficile Infection
A1  - Drekonja, Dimitri
A1  - Holzbauer, Stacy
A2  - Boulton, Matthew L.
A2  - Wallace, Robert B.
Y1  - 2022
N1  - 
T2  - Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e
AB  - Clostridioides  difficile  (formerly  known  as  Clostridium  difficile)  infection  (CDI)  has  emerged  as  a  pathogen  of  major  importance  among  hospitalized  and  ambulatory  patients.  It  now  rivals  methicillin-resistant  Staphylococcus  aureus  (MRSA)  as  the  leading  cause  of  nosocomial  infections,1  and  is  increasingly  encountered  among  ambulatory  patients,2  often  with  little  to  no  prior  contact  with  the  healthcare  system.  Because  of  increased  incidence  and  severity,  and  the  high  likelihood  of  recurrent  disease  after  initial  successful  treatment,  CDI  has  imposed  a  large  burden  on  healthcare  systems  across  the  world.  This  burden  is  manifested  by  a  high  rate  of  morbidity  and  mortality,  financial  costs,  and  a  high  consumption  of  healthcare  time  and  effort  devoted  to  testing,  infection  control,  cleaning,  and  reporting.3  Because  of  this  substantial  impact  on  the  healthcare  system,  the  United  States  Centers  for  Diseases  Control  and  Prevention  (CDC)  designated  C.  difficile  as  one  of  five  “urgent”  threats  in  its  2019  Antimicrobial  Resistance  Threat  Report,4  joining  drug-resistant  Neisseria  gonorrhoeae,  carbapenem-resistant  Enterobacteriaceae,  carbapenem-resistant  Acinetobacter,  and  Candida  auris  in  this  top  tier.  Challenges  and  controversies  regarding  epidemiology,  testing,  treatment,  prevention,  and  transmission  of  C.  difficile  have  emerged  (and  sometimes  re-emerged)  over  the  past  two  decades,  creating  difficulties  for  clinicians  and  persisting  questions  for  researchers  studying  CDI.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1182668351
ER  -